{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:02:19Z","timestamp":1791259339591,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013927","name":"National MPS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012233","name":"Abeona Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012233","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Allievex"},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008484","name":"BioMarin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016508","name":"bluebird bio","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016508","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017117","name":"Denali Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017117","id-type":"DOI","asserted-by":"crossref"}]},{"name":"JCR Pharmaceutical"},{"name":"Orchard Therapeutics"},{"DOI":"10.13039\/100013394","name":"ReGenXBio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seelos Therapeutics"},{"name":"Takeda"},{"DOI":"10.13039\/100013220","name":"Ultragenyx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012235","name":"Aeglea Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ymgme.2020.08.007","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T11:31:53Z","timestamp":1598873513000},"page":"181-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Therapy development for the mucopolysaccharidoses: Updated consensus recommendations for neuropsychological endpoints"],"prefix":"10.1016","volume":"131","author":[{"given":"Johanna H.","family":"van der Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Eisengart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Escolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Rust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Semrud-Clikeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.08.007_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mehy.2010.07.044","article-title":"Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?","volume":"75","author":"Wegrzyn","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - neurological signs and symptoms","volume":"122S","author":"Shapiro","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/adc.73.1.77","article-title":"Behaviour in mucopolysaccharide disorders","volume":"73","author":"Bax","year":"1995","journal-title":"Arch Dis Child"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2020.08.007_bb0025","first-page":"133","article-title":"Mucopolysaccharidosis III (Sanfilippo syndrome) - disease presentation and experimental therapies","volume":"12","author":"Gilkes","year":"2014","journal-title":"Pediatr Endocrinol Rev"},{"issue":"5","key":"10.1016\/j.ymgme.2020.08.007_bb0030","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2020.08.007_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00710053","article-title":"Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation","volume":"18","author":"Shapiro","year":"1995","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0165-5876(90)90215-D","article-title":"Degeneration of speech, language, and hearing in a patient with mucopolysaccharidosis VII","volume":"19","author":"Wallace","year":"1990","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"20","key":"10.1016\/j.ymgme.2020.08.007_bb0050","doi-asserted-by":"crossref","first-page":"e2321","DOI":"10.1212\/WNL.0000000000007496","article-title":"Attention and corpus callosum volumes in individuals with mucopolysaccharidosis type I","volume":"92","author":"King","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2014.12.299","article-title":"Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II","volume":"114","author":"Yund","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10545-011-9430-5","article-title":"Intellectual and neurological functioning in Morquio syndrome (MPS IVa)","volume":"36","author":"Davison","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1399-0004.2004.00277.x","article-title":"Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI","volume":"66","author":"Azevedo","year":"2004","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0075","series-title":"Rare diseases: common issues in drug development guidance for industry","author":"Food and Drug Administration","year":"2019"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.ymgme.2020.08.007_bb0085","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood.V87.11.4894.bloodjournal87114894","article-title":"Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome","volume":"87","author":"Peters","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ymgme.2020.08.007_bb0090","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.V91.7.2601","article-title":"Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group","volume":"91","author":"Peters","year":"1998","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ymgme.2020.08.007_bb0095","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/j.1651-2227.2008.00811.x","article-title":"Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT)","volume":"97","author":"Malm","year":"2008","journal-title":"Acta Paediatr"},{"issue":"5","key":"10.1016\/j.ymgme.2020.08.007_bb0100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.24246","article-title":"Early treatment is associated with improved cognition in Hurler syndrome","volume":"76","author":"Poe","year":"2014","journal-title":"Ann Neurol"},{"issue":"13","key":"10.1016\/j.ymgme.2020.08.007_bb0105","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ymgme.2020.08.007_bb0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ymgme.2018.02.011","article-title":"Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002\/MOR-100), representing 5 years of treatment","volume":"123","author":"Hendriksz","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10545-016-9973-6","article-title":"Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome","volume":"39","author":"Hendriksz","year":"2016","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0130","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/pr.2015.169","article-title":"Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y","volume":"78","author":"Jones","year":"2015","journal-title":"Pediatr Res"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0145","first-page":"77","article-title":"Long-term functional outcomes of children with hurler syndrome treated with unrelated umbilical cord blood transplantation","volume":"20","author":"Coletti","year":"2015","journal-title":"JIMD Rep"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2017.05.004","article-title":"Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure","volume":"121","author":"van der Lee","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0155","series-title":"The RAND UCLA appropriateness method user's manual","author":"Fitch","year":"2001"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0160","series-title":"The Delphi method: techniques and applications","author":"Linstone","year":"1975"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0165","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ymgme.2007.11.002","article-title":"A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency","volume":"93","author":"Arnold","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2008.09.008","article-title":"A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency","volume":"96","author":"Arnold","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.11.079","article-title":"A prospective natural history study of mucopolysaccharidosis type IIIA","volume":"170","author":"Shapiro","year":"2016","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2016.08.002","article-title":"A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design","volume":"119","author":"Truxal","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpeds.2018.01.044","article-title":"Observational prospective natural history of patients with Sanfilippo syndrome type B","volume":"197","author":"Whitley","year":"2018","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0195","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10545-013-9661-8","article-title":"Natural history of Sanfilippo syndrome type A","volume":"37","author":"Buhrman","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"10.1016\/j.ymgme.2020.08.007_bb0200","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","article-title":"Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: a phase IIb randomized trial","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur J Pediatr"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0215","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.ymgme.2020.08.007_bb0225","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","article-title":"Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison","volume":"20","author":"Eisengart","year":"2018","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0230","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13023-018-0817-3","article-title":"Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome","volume":"13","author":"Shapiro","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-017-0583-7","article-title":"Early disease progression of Hurler syndrome","volume":"12","author":"Kiely","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0240","first-page":"250","article-title":"Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation","volume":"2","author":"Peters","year":"1998","journal-title":"Pediatr Transplant"},{"issue":"9","key":"10.1016\/j.ymgme.2020.08.007_bb0245","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/gim.2016.223","article-title":"Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1","volume":"19","author":"Grosse","year":"2017","journal-title":"Genet Med"},{"issue":"457","key":"10.1016\/j.ymgme.2020.08.007_bb0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1651-2227.2008.00651.x","article-title":"Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective","volume":"97","author":"Martin","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0255","first-page":"129","article-title":"Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome","volume":"13","author":"Delaney","year":"2014","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0260","series-title":"Vineland adaptive behavior scales","author":"Sparrow","year":"2016"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0265","series-title":"Vineland Adaptive Behavior Scales","author":"Sparrow","year":"2005"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2017.05.005","article-title":"Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: a review of the literature","volume":"121","author":"Janzen","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0275","first-page":"S103","article-title":"Neurodevelopmental status and adaptive behavior of pediatric patients with Hunter syndrome: a longitudinal observational study","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0280","first-page":"100484","article-title":"A longitudinal study of neurocognition and behavior in patients with Hurler-Scheie syndrome heterozygous for the L238Q mutation","volume":"20","author":"Ahmed","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0285","series-title":"13th International MPS Symposium, Costa do Sauipe, Bahia, Brazil","article-title":"Natural history of language and motor function in MPS IIIA","author":"Shapiro","year":"2014"},{"issue":"11","key":"10.1016\/j.ymgme.2020.08.007_bb0290","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2522\/ptj.20070017","article-title":"Gross motor development of children with Hurler syndrome after umbilical cord blood transplantation","volume":"87","author":"Dusing","year":"2007","journal-title":"Phys Ther"},{"issue":"8","key":"10.1016\/j.ymgme.2020.08.007_bb0295","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2522\/ptj.20060196","article-title":"Temporal and spatial gait characteristics of children with Hurler syndrome after umbilical cord blood transplantation","volume":"87","author":"Dusing","year":"2007","journal-title":"Phys Ther"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0300","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ymgme.2015.02.008","article-title":"Quantifying behaviors of children with Sanfilippo syndrome: the Sanfilippo Behavior Rating Scale","volume":"114","author":"Shapiro","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0305","first-page":"100549","article-title":"The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome","volume":"22","author":"Eisengart","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0310","first-page":"87","article-title":"Psychological health in adults with Morquio syndrome","volume":"20","author":"Ali","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0315","doi-asserted-by":"crossref","first-page":"160018","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci Data"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcf.2018.03.001","article-title":"Cystic fibrosis patient registries: a valuable source for clinical research","volume":"17","author":"Dasenbrook","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-67144-4_5","article-title":"Natural history, trial readiness and gene discovery: advances in patient registries for neuromuscular disease","volume":"1031","author":"Thompson","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0330","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/13854046.2017.1422277","article-title":"Deciding to adopt revised and new psychological and neuropsychological tests: an inter-organizational position paper","volume":"32","author":"Bush","year":"2018","journal-title":"Clin Neuropsychol"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0335","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/arclin\/acs027","article-title":"Computerized neuropsychological assessment devices: joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology","volume":"27","author":"Bauer","year":"2012","journal-title":"Arch Clin Neuropsychol"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0340","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/23279095.2018.1460371","article-title":"Trail making test: comparison of paper-and-pencil and electronic versions","volume":"26","author":"Bracken","year":"2019","journal-title":"Appl Neuropsychol Adult"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0345","series-title":"Bayley Scales of Infant and Toddler Development: Fourth Edition (Bayley-4)","author":"Bayley","year":"2019"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0350","series-title":"Wechsler preschool and primary scale of intelligence, Technical Manual and Interpretive Manual","author":"Wechsler","year":"2012"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0355","series-title":"Wechsler intelligence scale for children, Technical Manual and Interpretive Manual","author":"Wechsler","year":"2014"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0360","series-title":"Differential Ability Scales (2nd ed)","author":"Elliott","year":"2007"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0365","series-title":"Kaufman Assessment Battery for Children, Second Edition","author":"Kaufman","year":"2004"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0370","first-page":"41","article-title":"The neurobehavioral phenotype in mucopolysaccharidosis type IIIB: an exploratory study","volume":"6","author":"Shapiro","year":"2016","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0375","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"10","key":"10.1016\/j.ymgme.2020.08.007_bb0380","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021734","article-title":"Psychometric properties of gross motor assessment tools for children: a systematic review","volume":"8","author":"Griffiths","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0385","series-title":"Peabody Developmental Motor Scales, Examiner\u2019s Manual","author":"Folio","year":"2000"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0390","series-title":"Bruininks-Oseretsky test of motor proficiency","author":"Bruininks","year":"2005"},{"issue":"11","key":"10.1016\/j.ymgme.2020.08.007_bb0395","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-8749.2006.02027a.x","article-title":"Gross motor abilities in children with Hurler syndrome","volume":"48","author":"Dusing","year":"2006","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0400","first-page":"53","article-title":"Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population","volume":"49","author":"Haller","year":"2019","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0405","first-page":"32","article-title":"A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II","volume":"7","author":"Shapiro","year":"2016","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0410","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ymgme.2019.11.118","article-title":"Evidence of problems with \u201cprocessing efficiency\u201d in attenuated mucopolysaccharidosis type I","volume":"129","author":"Eisengart","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0415","first-page":"27","article-title":"Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI","volume":"7","author":"Ahmed","year":"2016","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0420","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10545-015-9895-8","article-title":"Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome","volume":"39","author":"Ebbink","year":"2016","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0425","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/j.ymgme.2018.12.353","article-title":"Evidence of attention problems in Morquio syndrome","volume":"126","author":"Spurlock","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0430","series-title":"A compendium of neuropsychological tests: administration, norms, and commentary","author":"Strauss","year":"2006"},{"issue":"9","key":"10.1016\/j.ymgme.2020.08.007_bb0435","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1651-2227.2012.02680.x","article-title":"Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families","volume":"101","author":"Malcolm","year":"2012","journal-title":"Acta Paediatr"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0440","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13023-019-1233-z","article-title":"Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII - a European caregiver survey","volume":"14","author":"Morrison","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0445","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/13803395.2013.804035","article-title":"Mucopolysaccharidosis type IIIA presents as a variant of Kluver-Bucy syndrome","volume":"35","author":"Potegal","year":"2013","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0450","doi-asserted-by":"crossref","DOI":"10.12968\/bjon.2016.25.1.22","article-title":"Management of the behavioural manifestations of Hunter syndrome","volume":"25","author":"Roberts","year":"2016","journal-title":"Br J Nurs"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0455","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13023-019-1150-1","article-title":"Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data","volume":"14","author":"Shapiro","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0460","series-title":"Manual for the Child Behavior Checklist\/4-18 and 1991 Profile","author":"Achenbach","year":"1991"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0465","series-title":"BRIEF: Behavior Rating Inventory of Executive Function","author":"Gioia","year":"2013"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0470","series-title":"Behavior assessment system for children","author":"Reynolds","year":"2004"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0475","series-title":"Behavior Assessment System for Children, Third Edition (BASC-3)","author":"Reynolds","year":"2015"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0480","first-page":"100566","article-title":"Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome","volume":"22","author":"Grant","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0485","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.ymgme.2018.12.285","article-title":"Meaningful treatment outcomes for Sanfilippo syndrome: a study of caregiver preferences and prioritization","volume":"126","author":"O\u2019Neill","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0490","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s41687-019-0140-3","article-title":"Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the Caregiver Impact Questionnaire","volume":"3","author":"Harrington","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0495","author":"Open-label study of anakinra in MPS III (NCT04018755)"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0500","series-title":"A long-term follow-up study of patients with MPS IIIA treated with ABO-102 (NCT04360265)","year":"2020"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0505","series-title":"A study of mucopolysaccharidosis type IIIB (MPS IIIB) (NCT02493998)","year":"2020"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0510","series-title":"A study of patients with Sanfilippo syndrome type A (MPS IIIA) (NCT01047306)","year":"2016"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0515","series-title":"Safety, tolerability, ascending dose and dose frequency study of rhHNS via an IDDD in MPS IIIA patients (NCT01155778)","year":"2018"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0520","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1477-7525-1-81","article-title":"Health related quality of life in 3 and 4 year old children and their parents: preliminary findings about a new questionnaire","volume":"1","author":"Klassen","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0525","series-title":"Child Health Questionnaire (CHQ): a user's manual","author":"Landgraf","year":"1996"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0530","series-title":"A study to assess the safety, tolerability, and efficacy of long-term SOBI003 treatment in pediatric MPS IIIA patients (NCT03811028)","year":"2020"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0535","series-title":"A study to assess the safety and rolerability of SOBI003 in pediatric MPS IIIA patients (NCT03423186)","year":"2020"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0540","series-title":"Gene transfer clinical trial for mucopolysaccharidosis (MPS) IIIB (MPSIIIB) (NCT03315182)","year":"2020"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2020.08.007_bb0545","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10198-016-0787-0","article-title":"Social\/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe","volume":"17","author":"Pentek","year":"2016","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0550","series-title":"Parenting Stress Index (4th edition)","author":"Abidin","year":"2012"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0555","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-7525-2-55","article-title":"The PedsQL Family Impact Module: preliminary reliability and validity","volume":"2","author":"Varni","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0560","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/geront\/20.6.649","article-title":"Relatives of the impaired elderly: correlates of feelings of burden","volume":"20","author":"Zarit","year":"1980","journal-title":"Gerontologist"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0565","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-012-9558-y","article-title":"Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID)","volume":"36","author":"Grant","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0570","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1442-200X.2008.02652.x","article-title":"Psychological status of patients with mucopolysaccharidosis type II and their parents","volume":"51","author":"Kuratsubo","year":"2009","journal-title":"Pediatr Int"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0575","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13023-016-0521-0","article-title":"Parents' experiences of living with, and caring for children, adolescents and young adults with mucopolysaccharidosis (MPS)","volume":"11","author":"Somanadhan","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0580","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","article-title":"Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues","volume":"11","author":"Hendriksz","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0585","first-page":"95","article-title":"Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (Hurler syndrome) treated with hematopoietic cell transplantation","volume":"29","author":"Kunin-Batson","year":"2016","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0590","doi-asserted-by":"crossref","DOI":"10.1177\/2326409815576188","article-title":"Relationship between patient-reported outcomes and clinical outcomes in patients with Morquio A syndrome","volume":"3","author":"Lampe","year":"2015","journal-title":"J Inborn Errors Metab Screening"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0595","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","article-title":"Health-related quality of life in patients with MPS II","volume":"24","author":"Needham","year":"2015","journal-title":"J Genet Couns"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0600","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ymgme.2016.01.012","article-title":"Elevated TNF-alpha is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI","volume":"117","author":"Polgreen","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0605","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.ymgme.2020.08.007_bb0610","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.ymgme.2020.08.007_bb0615","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0620","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.01.003","article-title":"The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII","volume":"129","author":"Wang","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0625","series-title":"SF-36 physical and mental health summary scales: a users' manual","author":"Ware","year":"1994"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0630","first-page":"586","article-title":"Rationale and development of a functional disability outcomes measure for MPS I","volume":"71","author":"Skrinar","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0635","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1750-1172-8-101","article-title":"The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life","volume":"8","author":"Raluy-Callado","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.ymgme.2020.08.007_bb0640","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s11136-014-0703-y","article-title":"The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation","volume":"23","author":"Wiklund","year":"2014","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0645","first-page":"S121","article-title":"Parent prioritization of meaningful treatment targets for Sanfilippo syndrome","volume":"129","author":"O'Neill","year":"2020","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0650","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2013.03.004","article-title":"High prevalence of femoral head necrosis in mucopolysaccharidosis type III (Sanfilippo disease): a national, observational, cross-sectional study","volume":"109","author":"de Ruijter","year":"2013","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.ymgme.2020.08.007_bb0655","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BPO.0b013e31821f5ee9","article-title":"Musculoskeletal manifestations of Sanfilippo Syndrome (mucopolysaccharidosis type III)","volume":"31","author":"White","year":"2011","journal-title":"J Pediatr Orthop"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0660","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10545-014-9737-0","article-title":"Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey","volume":"38","author":"Brands","year":"2015","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"10.1016\/j.ymgme.2020.08.007_bb0665","first-page":"609","article-title":"Preliminary validation of an observational pain checklist for persons with cognitive impairments and inability to communicate verbally","volume":"42","author":"Breau","year":"2000","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"10.1016\/j.ymgme.2020.08.007_bb0670","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/00000539-200211000-00020","article-title":"The reliability and validity of the Face, Legs, Activity, Cry, Consolability observational tool as a measure of pain in children with cognitive impairment","volume":"95","author":"Voepel-Lewis","year":"2002","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.ymgme.2020.08.007_bb0675","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-017-0675-4","article-title":"Recommendations on clinical trial design for treatment of mucopolysaccharidosis Type III","volume":"12","author":"Ghosh","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.ymgme.2020.08.007_bb0680","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/sim.8050","article-title":"Bayesian model of disease progression in GNE myopathy","volume":"38","author":"Quintana","year":"2019","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0685","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10545-012-9572-0","article-title":"Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders","volume":"36","author":"Cross","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020500","article-title":"Genome editing for mucopolysaccharidoses","volume":"21","author":"Poletto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0695","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122S","author":"Scarpa","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0700","series-title":"Wechsler adult intelligence scale, Technical Manual and Interpretive Manual","author":"Wechsler","year":"2008"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0705","series-title":"Wechsler abbreviated scale of intelligence, Technical Manual and Interpretive Manual","author":"Wechsler","year":"2011"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0710","series-title":"TOVA: Test of Variables of Attention, Clinical Manual","author":"Greenberg","year":"2018"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0715","series-title":"Conners Continuous Performance Test 3rd Edition (Conners CPT 3)","author":"Connors","year":"2014"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0720","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymgme.2019.11.007","article-title":"Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study","volume":"129","author":"Chen","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0725","series-title":"Hopkins Verbal Learning Test - Revised, Professional Manual","author":"Brandt","year":"1998"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0730","series-title":"Rey Auditory Verbal Learning Test, A Handbook","author":"Schmidt","year":"1996"},{"issue":"92","key":"10.1016\/j.ymgme.2020.08.007_bb0735","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ymgme.2007.08.036","article-title":"Hippocampal functions in MPS I: a pilot study of memory encoding and visual spatial function","volume":"4","author":"Shapiro","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0740","series-title":"Beery Buktenica Developmental Test of Visual Motor Integration","author":"Beery","year":"2010"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0745","series-title":"Rey-Osterrieth Complex Figure Usage: Clinical and Research Applications","author":"Knight","year":"2004"},{"issue":"3","key":"10.1016\/j.ymgme.2020.08.007_bb0750","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/nedt.2006.2.3.381","article-title":"Longitudinal neurocognitive outcome in an adolescent with Hurler-Scheie syndrome","volume":"2","author":"Elkin","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0755","series-title":"Purdue Pegboard Test, User Instructions","year":"2015"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0760","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/153944928500500102","article-title":"Adult norms for the nine hole peg test of finger dexterity","volume":"5","author":"Mathiowetz","year":"1985","journal-title":"Occupational Ther J Res"},{"issue":"4","key":"10.1016\/j.ymgme.2020.08.007_bb0765","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","article-title":"A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease","volume":"123","author":"Harmatz","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0770","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40259-019-00344-7","article-title":"Vestronidase alfa: a review in mucopolysaccharidosis VII","volume":"33","author":"McCafferty","year":"2019","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0775","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.ymgme.2019.11.335","article-title":"Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): symptoms and the impact on function and activities of daily living (ADL)","volume":"129","author":"Phillips","year":"2020","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0780","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2013.11.014","article-title":"Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the alpha-L-iduronidase gene in Hurler-Scheie syndrome","volume":"111","author":"Ahmed","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0785","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.ymgme.2015.12.321","article-title":"Emotional-behavioral functioning in individuals with MPS I: a longitudinal approach","volume":"117","author":"King","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.ymgme.2020.08.007_bb0790","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2214.2008.00918.x","article-title":"Psychosocial outcomes of bone marrow transplant for individuals affected by Mucopolysaccharidosis I Hurler Disease: patient social competency","volume":"35","author":"Pitt","year":"2009","journal-title":"Child Care Health Dev"},{"issue":"6","key":"10.1016\/j.ymgme.2020.08.007_bb0795","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/02643294.2017.1401530","article-title":"Cognitive and behaviour profiles of children with mucopolysaccharidosis type II","volume":"34","author":"Crowe","year":"2017","journal-title":"Cogn Neuropsychol"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0800","first-page":"75","article-title":"Social functioning and behaviour in mucopolysaccharidosis IH [Hurlers syndrome]","volume":"39","author":"Lehtonen","year":"2018","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0810","author":"NIH Toolbox"},{"key":"10.1016\/j.ymgme.2020.08.007_bb0815","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ymgme.2012.11.128","article-title":"Visual memory and working memory as assessed by a computerized measure in individuals with mucopolysaccharidosis, type I (MPSI)","volume":"108","author":"King","year":"2013","journal-title":"Mol Genet Metab"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922030189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922030189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:25:59Z","timestamp":1761089159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671922030189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":162,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S109671922030189X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.08.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy development for the mucopolysaccharidoses: Updated consensus recommendations for neuropsychological endpoints","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}